- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06096116
Studie fáze 3 o účinnosti a bezpečnosti antitrombinu derivovaného z lidské plazmy (Atenativ) u pacientů rezistentních na heparin, u kterých je plánována kardiochirurgická operace vyžadující kardiopulmonální bypass
Fáze 3, dvojitě zaslepená, placebem kontrolovaná, multicentrická studie o účinnosti a bezpečnosti antitrombinu derivovaného z lidské plazmy (Atenativ) u pacientů rezistentních na heparin, kteří mají podstoupit kardiochirurgický výkon vyžadující kardiopulmonální bypass
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Cristina Solomon, MD
- Telefonní číslo: +41 79 585 90 42
- E-mail: Cristina.Solomon@octapharma.com
Studijní místa
-
-
-
Reims, Francie
- Ukončeno
- CHU de Reims, Hôpital Robert Debré
-
Rennes, Francie
- Staženo
- CHU de Rennes
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Kanada, V3L0A4
- Nábor
- Royal Columbian Hospital
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L2V7
- Nábor
- Kingston Health Sciences Centre
-
Toronto, Ontario, Kanada, M5G2C4
- Zatím nenabíráme
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T1C8
- Nábor
- Montreal Heart Institute
-
-
-
-
-
Kaunas, Litva
- Ukončeno
- Hospital of Lithuanian university of Health sciences Kauno Klinikos
-
Vilnius, Litva
- Nábor
- Vilnius University hospital Santaros Klinikos
-
-
-
-
-
Innsbruck, Rakousko
- Nábor
- University Hospital Innsbruck
-
Vienna, Rakousko
- Nábor
- Vienna General Hospital AKH, Medical University of Vienna
-
-
-
-
-
Bucharest, Rumunsko
- Nábor
- Institute for Cardiovascular Diseases C.C. Iliescu
-
-
-
-
-
Ljubljana, Slovinsko
- Nábor
- University Medical Centre Ljubljana
-
-
-
-
-
Cambridge, Spojené království
- Nábor
- Royal Papworth Hospital
-
Coventry, Spojené království
- Nábor
- University Hospital Coventry and Warwickshire
-
Middlesbrough, Spojené království
- Nábor
- The James Cook University Hospital
-
-
-
-
California
-
Stanford, California, Spojené státy, 94305-5101
- Nábor
- Stanford University School of Medicine
-
-
Florida
-
Miami, Florida, Spojené státy, 33136
- Nábor
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Nábor
- Massachusetts General Hospital
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710-1000
- Nábor
- Duke University Medical Center
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Nábor
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44195
- Nábor
- Cleveland Clinic
-
Columbus, Ohio, Spojené státy, 43214
- Nábor
- The Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- Nábor
- OU Health University of Oklahoma Medical Center
-
-
Texas
-
Dallas, Texas, Spojené státy, 75390
- Nábor
- University of Texas Southwestern Medical Center
-
-
-
-
-
Kamenitz, Srbsko
- Nábor
- Institute of Cardiovascular Diseases Vojvodina
-
-
-
-
-
Brno, Česko
- Nábor
- Center of Cardiovascular and Transplant Surgery
-
Prague, Česko
- Ukončeno
- Institute for Clinical and Experimental Medicine
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Planned cardiac surgery with CPB
- Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
- Patients between 18 and 85 years of age, inclusive
- Freely given written or electronic informed consent
- In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery
Exclusion Criteria:
-
Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:
- vitamin K antagonists (within 3 days)
- direct oral anticoagulants (within 2 days)
- thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- glycoprotein IIb/IIIa antagonist (within 24 hours)
-
Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)
-
Renal insufficiency, defined as serum creatinine level >2.0 mg/dL
-
Thrombocytosis, defined as platelet count >400,000 per μL
-
Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid
-
History of anaphylactic reaction(s) to blood or blood components
-
Refusal to receive transfusion of blood or blood-derived products
-
Current participation in another interventional clinical trial or previous participation in the current trial
-
Treatment with any IMP within 30 days prior to screening visit
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Low-dose Atenativ
Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Experimentální: High-dose Atenativ
Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Komparátor placeba: Placebo
Patients will receive a saline bolus dose |
Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Restoring heparin responsiveness
Časové okno: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Amounts of further therapy for restoring heparin responsiveness
Časové okno: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Change in activated clotting time (ACT) values
Časové okno: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo |
Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
|
Change in antithrombin plasma levels
Časové okno: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo |
Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
|
Change in heparin usage
Časové okno: From end of IMP infusion to the end of surgery
|
The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo |
From end of IMP infusion to the end of surgery
|
|
FP unit use
Časové okno: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
|
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Časové okno: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first) |
From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
|
Transfusion of allogenic blood products
Časové okno: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of coagulation factor concentrates
Časové okno: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of other haemostatic-relevant therapies
Časové okno: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Postoperative chest tube drainage
Časové okno: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first |
From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Need for reoperation due to bleeding
Časové okno: 24 hours after the start of IMP infusion
|
Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical) |
24 hours after the start of IMP infusion
|
|
Cell saver volume
Časové okno: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between cell saver volume until the end of surgery |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Adverse events
Časové okno: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
Incidence of adverse events, including all related and non-related, non-serious adverse events |
From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
|
Serious adverse events
Časové okno: From the start of IMP infusion until 28 days after IMP administration
|
Incidence of serious adverse events |
From the start of IMP infusion until 28 days after IMP administration
|
|
Survival status
Časové okno: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
Number of patients surviving in all three cohorts |
At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
|
Red Blood Cell count
Časové okno: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
White Blood Cell count
Časové okno: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haemoglobin levels
Časové okno: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haematocrit
Časové okno: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
|
Platelet count
Časové okno: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ATN-108
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .